Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other pharmaceutical manufacturers in Australasia: AFT Pharmaceuticals Ltd of NEW ZEALAND (2020 sales of 105.60 million New Zealand Dollars [US$74.05 million] of which 58% was Australia), Probiotec Limited (107.22 million Australian Dollars [US$81.66 million] ), and Vita Life Sciences Limited. (46.48 million Australian Dollars [US$35.40 million] ).

Sales Analysis. During the year ended June of 2020, sales at Mayne Pharma Group Limited were A$457.77 million (US$348.64 million). This is a decrease of 13.0% versus 2019, when the company's sales were A$526.22 million. Contributing to the drop in overall sales was the 21.1% decline in Generic Products, from A$320.77 million to A$253.05 million. There were also decreases in sales in Specialty Brands (down 14.0% to A$78.76 million) . However, these declines were partially offset by the increase in sales of Metrics Contract Services (Mcs) (up 14.7% to A$82.82 million) and Mayne Pharma International (Mpi) (up 4.1% to A$42.36 million) .